Skip to content

Ayurvedic management of Madhumehajanya Upadrava(Diabetic kidney disease)

Efficacy of Add-on administration of Nishakatakadi Kwatha and Punarnava-Gokshura Vardhamana Rasayana in the management of Madhumehajanya Upadrava (Diabetic Kidney Disease)-An open labelled randomised standard controlled clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/083987
Enrollment
30
Registered
2025-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

None listed

Sponsors

Institute of Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex of age group between 18 to 65 yrs Both freshly detected and previously diagnosed cases of diabetic kidney disease Patients with a clinical positive history of type 1 and type 2 DM Patients with microalbumin between 30 to 299 mg/L in random urine sample Patients with eGFR between 30 to 89 ml/min/1.73 m Patient willing to participate in the study

Exclusion criteria

Exclusion criteria: Patient aged below 18 years and above 65 years Patients with microalbumin greater or equal to 300 mg/ L in random urine sample Microalbuminuria developed due to other conditions (such as urinary tract infections other febrile infections recent exercise heart failure and uncontrolled hyperglycemia or hypertension) Patient with other severe complication of Diabetes Mellitus Patients with an eGFR (glomerular filtration rate) less than 30 ml/min/1.73m Patients with serum creatinine level above 5 mg/dl Pregnant and lactating women and during post -delivery period Any other severe systemic illness such as HIV TB malignancies cardio-vascular disease Patients with uncontrolled blood pressure (BP greater than 160/90mmhg) will be excluded

Design outcomes

Primary

MeasureTime frame
Improvement in renal function (decrease in serum creatinine microalbuminuria and improvement in eGFR)Timepoint: GROUP-A 8 WEEKS GROUP-B 8 WEEKS

Secondary

MeasureTime frame
Improvement in glycemic control Reduction in high blood pressure Improvement in the quality of life of patient having diabetic nephropathyTimepoint: GROUP-A 8 WEEKS GROUP-B 8 WEEKS

Countries

India

Contacts

Public ContactDr Megha Pandya

Institute of teaching and research in Ayurveda

doctor.megha01@gmail.com9409714186

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026